Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LTA4H | P09960 | 2/20 | 0.44 |
| ▸ | CA1 | P00915 | 1/20 | 0.42 |
| ▸ | CA2 | P00918 | 1/20 | 0.42 |
| ▸ | CA9 | Q16790 | 1/20 | 0.42 |
| ▸ | PDE4A | P27815 | 1/20 | 0.41 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.41 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.41 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.41 |
| ▸ | SCN9A | Q15858 | 4/20 | 0.40 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.40 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.40 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.40 |
| ▸ | KIF11 | P52732 | 2/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | MAOB | P27338 | 1/20 | 0.38 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.37 |
| ▸ | HTR2A | P28223 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1685383 | 0.86 | CA1 (0.52) | LTA4HCA1CA2CA9PDE4A | |
| SCHEMBL11148692 | 0.86 | CA1 (0.52) | LTA4HCA1CA2CA9PDE4A | |
| SCHEMBL29377645 | 0.84 | LTA4H (0.50) | LTA4HCA1CA2CA9PDE4A | |
| SCHEMBL1283659 | 0.83 | TLR8 (0.41) | SCN9ARAB9AL3MBTL1 | |
| SCHEMBL3992787 | 0.80 | AGXT (0.42) | LTA4HPDE4APDE4BPDE4CPDE4D | |
| SCHEMBL5693992 | 0.79 | CHRNB2 (0.43) | LTA4HCA1CA2MAOBHTR2A | |
| SCHEMBL921675 | 0.79 | MAPK14 (0.41) | LTA4HCA1CA2CA9PDE4A | |
| SCHEMBL694092 | 0.79 | LTA4H (0.49) | LTA4HSCN9AKIF11L3MBTL1SLC6A4 | |
| SCHEMBL2903224 | 0.79 | MAPT (0.43) | LTA4HSCN9AKCNH2RAB9ATTBK1 | |
| SCHEMBL920510 | 0.78 | EPHX2 (0.42) | LTA4HSCN9AKCNH2SCN5AKIF11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 112 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230339904-A1 | ISOINDOLINONES, PHARMACEUTICAL COMPOSITIONS, AND THERAPEUTIC APPLICATIONS | BIOTHERYX, INC. | 2023-10-26 | — | — | US | claimed |
| EP-1880720-B1 | SUBSTITUTED ACRYLAMIDE DERIVATIVE AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | DAIICHI SANKYO CO LTD (JP) | 2013-02-13 | — | — | EP | claimed |
| WO-2010012793-A1 | FUNGICIDE AMINOTHIAZOLE DERIVATIVES | BAYER CROPSCIENCE SA (FR) | 2010-02-04 | — | — | WO | claimed |
| EP-1648886-B1 | BENZOXAZINONE-DERIVED SULFONAMIDE COMPOUNDS, THEIR PREPARATION AND USE AS MEDICAMENTS | ESTEVE LABOR DR (ES) | 2009-12-09 | — | — | EP | claimed |
| US-20090292024-A1 | SUBSTITUTED PROPANAMIDE DERIVATIVE AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2009-11-26 | — | — | US | claimed |
| US-20090118199-A1 | SUBSTITUTED ACRYLAMIDE DERIVATIVE AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | DAIICHI SANKYO COMPANY , LIMITED (JP) | 2009-05-07 | — | — | US | claimed |
| EP-1908466-A1 | SUBSTITUTED PROPANAMIDE DERIVATIVE AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME | Daiichi Sankyo Company, Limited (JP) | 2008-04-09 | — | — | EP | claimed |
| EP-1880720-A1 | SUBSTITUTED ACRYLAMIDE DERIVATIVE AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | Daiichi Sankyo Company, Limited (JP) | 2008-01-23 | — | — | EP | claimed |
| EP-1660439-A2 | ARYL AND HETEROARYL COMPOUNDS, COMPOSITIONS, AND METHODS OF USE | Transtech Pharma, Inc. (US) | 2006-05-31 | — | — | EP | claimed |
| EP-1470138-B1 | MMP INHIBITORS | LEO PHARMA AS (DK) | 2006-01-18 | — | — | EP | claimed |
| US-6784169-B2 | METALLOPROTEASE INHIBITOR; ANTIINFLAMAMTORY AGENTS; RHEUMATIC DISORDERS; CARDIOVASCULAR DISORDERS; CONTROLLING CELL PROLIFERATION | LEO PHARMACETICAL PRODUCTS LTD. (DK) | 2004-08-31 | — | — | US | claimed |
| US-20040110832-A1 | management, treatment and/or control of diseases caused in intrinsic clotting pathway utilizing factor IX such as stroke, myocardial infarction, aneurysm surgery, and deep vein thrombosis associated with surgical procedures etc | TRANSTECH PHARMA, LLC | 2004-06-10 | — | — | US | claimed |
| WO-2004014844-A2 | ARYL AND HETEROARYL COMPOUNDS AND METHODS TO MODULATE COAGULATION | TRANSTECH PHARMA, INC. (US) | 2004-02-19 | — | — | WO | claimed |
| US-20030191092-A1 | MMP inhibitors | CHRISTENSEN METTE KNAK (DK) | 2003-10-09 | — | — | US | claimed |
| WO-2003059921-A1 | MMP INHIBITORS | LEO PHARMA A/S (DK) | 2003-07-24 | — | — | WO | claimed |
| EP-1303527-A1 | MATRIX METALLOPROTEINASE INHIBITORS | Leo Pharma A/S (DK) | 2003-04-23 | — | — | EP | claimed |
| US-6521606-B2 | 2-(4-Chlorophenoxy)-2-oxo-1,3,2-oxazaphosphorinane-3-aceto -hydroxamic acid, for example; antiathritic, -tumor, -metastasis, -proliferative and -ulcer agents; multiple sclerosis; vision defects; skin disorders | LEO PHARMACEUTICAL PRODUCTS, LTD. A/S (DK) | 2003-02-18 | — | — | US | claimed |
| US-6509426-B2 | Dichloro(1,1'-dimethylsilylenebis(2-methyl-4-(4-methoxyphenyl) -4H-azulenyl))zirconium, for example; can produce polyolefin with high molecular weight and high melting point for extrusion or injection moldability | JAPAN POLYCHEM CORPORATION (JP) | 2003-01-21 | — | — | US | claimed |
| US-20020103166-A1 | Matrix metalloproteinase inhibitors | LEO PHARMACEUTICAL PRODUCTS, LTD. A/S (DK) | 2002-08-01 | — | — | US | claimed |
| WO-2002006293-A1 | MATRIX METALLOPROTEINASE INHIBITORS | LEO PHARMA A/S (DK) | 2002-01-24 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230339904-A1 | ISOINDOLINONES, PHARMACEUTICAL COMPOSITIONS, AND THERAPEUTIC APPLICATIONS | CSNK1A1, CSNK1D, CSNK1G1 | LTA4H 2841/4885CA1 566/4885CA2 216/4885 |
| US-20040110832-A1 | management, treatment and/or control of diseases caused in intrinsic clotting pathway utilizing factor IX such as stroke, myocardial infarction, aneurysm surgery, and deep vein thrombosis associated with surgical procedures etc | TFPI, F9, TFPI2 | LTA4H 650/4885CA1 2599/4885CA2 3413/4885 |
| US-20090292024-A1 | SUBSTITUTED PROPANAMIDE DERIVATIVE AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME | PTMS, C1S, ACP3 | LTA4H 1449/4885CA1 866/4885CA2 364/4885 |
| US-20030191092-A1 | MMP inhibitors | MMP11, MMP1, MMP13 | LTA4H 283/4885CA1 62/4885CA2 46/4885 |
| US-20090118199-A1 | SUBSTITUTED ACRYLAMIDE DERIVATIVE AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | ACR, NAT1, C1S | LTA4H 972/4885CA1 2630/4885CA2 1814/4885 |
| US-20020103166-A1 | Matrix metalloproteinase inhibitors | MMP1, MMP9, MMP8 | LTA4H 1781/4885CA1 39/4885CA2 171/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.